The RB tumor suppressor at the intersection of proliferation and immunity: Relevance to disease immune evasion and immunotherapy

Cell Cycle

Volumn 14, Issue 24, 2015, Pages 3812-3819

  Hutcheson, Jack ^a   Witkiewicz, Agnieszka K ^a,b   Knudsen, Erik S ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anti viral immunity; Differentiation; Immune function; Immunotherapy; RB; Transcription; Tumor suppressor

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INHIBITOR OF DIFFERENTIATION 2; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR PU 1;

ARTICLE; BCG VACCINATION; CANCER IMMUNOTHERAPY; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL DIVISION; CELL FATE; CELL PROLIFERATION; COLORECTAL CANCER; EYE TUMOR; GENE INACTIVATION; GENE REPRESSION; HEMATOPOIETIC STEM CELL; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; MELANOMA; MULTIPOTENT STEM CELL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR VIRUS; UTERINE CERVIX CANCER; ANIMAL; BIOLOGICAL MODEL; CELL CYCLE; IMMUNOTHERAPY; METABOLISM; PHYSIOLOGY; PROCEDURES; RETINOBLASTOMA;

ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN;

EID: 84964067257     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1010922     Document Type: Article

References (72)

1. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8:671-82; PMID:18650841; http://dx.doi.org/10.1038/nrc2399
2. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 8:714-24; PMID:19143056; http://dx.doi.org/10.1038/nrc2401
3. Miccadei S, Provenzano C, Mojzisek M, Natali PG, Civitareale D. Retinoblastoma protein acts as Pax 8 transcriptional coactivator. Oncogene 2005; 24:6993-7001; PMID:16007137; http://dx.doi.org/10.1038/sj.onc.1208861
4. Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC, Hinds PW. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 2001; 8:303-16; PMID:11545733; http://dx.doi.org/10.1016/S1097-2765(01)00327-6
5. Scott EW, Fisher RC, Olson MC, Kehrli EW, Simon MC, Singh H. PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity 1997; 6:437-47; PMID:9133423; http://dx.doi.org/10.1016/S1074-7613(00)80287-3
6. Kueh HY, Champhekar A, Nutt SL, Elowitz MB, Rothenberg EV. Positive feedback between PU.1 and the cell cycle controls myeloid differentiation. Science 2013; 341:670-3; PMID:23868921; http://dx.doi.org/10.1126/science.1240831
7. Kadri Z, Shimizu R, Ohneda O, Maouche-Chretien L, Gisselbrecht S, Yamamoto M, Romeo PH, Leboulch P, Chretien S. Direct binding of pRb/E2F-2 to GATA-1 regulates maturation and terminal cell division during erythropoiesis. PLoS Biol 2009; 7:e1000123; PMID:19513100; http://dx.doi.org/10.1371/journal.pbio.1000123
8. Rekhtman N, Choe KS, Matushansky I, Murray S, Stopka T, Skoultchi AI. PU.1 and pRB interact and cooperate to repress GATA-1 and block erythroid differentiation. Mol Cell Biol 2003; 23:7460-74; PMID:14559995; http://dx.doi.org/10.1128/MCB.23.21.7460-7474.2003
9. Charles A, Tang X, Crouch E, Brody JS, Xiao ZX. Ret-inoblastoma protein complexes with C/EBP proteins and activates C/EBP-mediated transcription. J Cell Biochem 2001; 83:414-25; PMID:11596110; http://dx.doi.org/10.1002/jcb.1239
10. Johnson-Pais T, Degnin C, Thayer MJ. pRB induces Sp1 activity by relieving inhibition mediated by MDM2. Proc Natl Acad Sci U S A 2001; 98:2211-6; PMID:11226218; http://dx.doi.org/10.1073/pnas.051415898
11. Jamal R, Gale RE, Shaun N, Thomas B, Wheatley K, Linch DC. The retinoblastoma gene (rb1) in acute myeloid leukaemia: analysis of gene rearrangements, protein expression and comparison of disease outcome. Br J Haematol 1996; 94:342-51; PMID:8759895; http://dx.doi.org/10.1046/j.1365-2141.1996.d01-1804.x
12. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007; 129:1081-95; PMID:17574022; http://dx.doi.org/10.1016/j.cell.2007.03.055
13. Viatour P, Somervaille TC, Venkatasubrahmanyam S, Kogan S, McLaughlin ME, Weissman IL, Butte AJ, Passegue E, Sage J. Hematopoietic stem cell quiescence is maintained by compound contributions of the reti-noblastoma gene family. Cell Stem Cell 2008; 3:416-28; PMID:18940733; http://dx.doi.org/10.1016/j.stem.2008.07.009
14. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45:242-52; PMID:23334668; http://dx.doi.org/10.1038/ng.2532
15. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991
16. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruz-zato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014; 1319:47-65; PMID:24965257; http://dx.doi.org/10.1111/nyas.12469
17. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 2012; 22:275-81; PMID:22313874; http://dx.doi.org/10.1016/j.semcancer.2012.01.011
18. Dai J, El Gazzar M, Li GY, Moorman JP, Yao ZQ. Myeloid-Derived Suppressor Cells: Paradoxical Roles in Infection and Immunity. J Innate Immun 2014; PMID:25401944
19. Youn JI, Kumar V, Collazo M, Nefedova Y, Cond-amine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, et al. Epigenetic silencing of retino-blastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 2013; 14:211-20; PMID:23354483; http://dx.doi.org/10.1038/ni.2526
20. Markey MP, Bergseid J, Bosco EE, Stengel K, Xu H, Mayhew CN, Schwemberger SJ, Braden WA, Jiang Y, Babcock GF, et al. Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function. Oncogene 2007; 26:6307-18; PMID:17452985; http://dx.doi.org/10.1038/sj.onc.1210450
21. Hutcheson J, Bourgo RJ, Balaji U, Ertel A, Witkiewicz AK, Knudsen ES. Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance to hepatocellular carcinoma. Hepatology 2014; PMID:24824777
22. Longworth MS, Walker JA, Anderssen E, Moon NS, Gladden A, Heck MM, Ramaswamy S, Dyson NJ. A shared role for RBF1 and dCAP-D3 in the regulation of transcription with consequences for innate immunity. PLoS Genet 2012; 8:e1002618; PMID:22496667; http://dx.doi.org/10.1371/journal.pgen.1002618
23. Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T. The critical role of type-1 innate and acquired immunity in tumor immunother-apy. Cancer science 2004; 95:697-703; PMID:15471553; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03248.x
24. Pulendran B, Artis D. New paradigms in type 2 immunity. Science 2012; 337:431-5; PMID:22837519; http://dx.doi.org/10.1126/science.1221064
25. Dalessandri T, Strid J. Beneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancer. Front Immunol 2014; 5:347; PMID:25101088; http://dx.doi.org/10.3389/fimmu.2014.00347
26. Urashima M, Ogata A, Chauhan D, Vidriales MB, Teoh G, Hoshi Y, Schlossman RL, DeCaprio JA, Anderson KC. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood 1996; 88:2219-27; PMID:8822942
27. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblas-toma susceptibility gene product. Proc Natl Acad Sci U S A 1991; 88:7605-9; PMID:1652755; http://dx.doi.org/10.1073/pnas.88.17.7605
28. Zhu YM, Bradbury DA, Keith FJ, Russell N. Absence of retinoblastoma protein expression results in auto-crine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia 1994; 8:1982-8; PMID:7967742
29. Zhu X, Pattenden S, Bremner R. pRB is required for interferon-gamma-induction ofthe MHC class II abeta gene. Oncogene 1999; 18:4940-7; PMID:10490828; http://dx.doi.org/10.1038/sj.onc.1202876
30. Lu Y, Tschickardt ME, Schmidt BJ, Blanck G. IFN gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to reti-noblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. Immunol Cell Biol 1997; 75:325-32; PMID:9315472; http://dx.doi.org/10.1038/icb.1997.50
31. Lu Y, Boss JM, Hu SX, Xu HJ, Blanck G. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction. J Immunol 1996; 156:2495-2502; PMID:8786310
32. Lu Y, Ussery GD, Jacim M, Tschickardt M, Boss JM, Blanck G. Retinoblastoma protein regulation ofsurface CD74 (invariant chain) expression in breast carcinoma cells. Mol Immunol 1994; 31:1365-8; PMID:7997248; http://dx.doi.org/10.1016/0161-5890(94)90055-8
33. Lu Y, Ussery GD, Muncaster MM, Gallie BL, Blanck G. Evidence for retinoblastoma protein (RB) dependent and independent IFN-gamma responses: RB coor-dinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells. Oncogene 1994; 9:1015-9; PMID:8134104
34. Osborne A, Tschickardt M, Blanck G. Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter. Nucleic Acids Res 1997; 25:5095-102; PMID:9396821; http://dx.doi.org/10.1093/nar/25.24.5095
35. Osborne AR, Zhang H, Blanck G. Oct-1 DNA binding activity unresponsive to retinoblastoma protein expression prevents MHC class II induction in a non-small cell lung carcinoma cell line. Mol Immunol 2006; 43:710-6; PMID:16360016; http://dx.doi.org/10.1016/j.molimm.2005.03.013
36. Osborne A, Zhang H, Yang WM, Seto E, Blanck G. Histone deacetylase activity represses gamma inter-feron-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chroma- tin conformation. Mol Cell Biol 2001; 21:6495-506; PMID:11533238; http://dx.doi.org/10.1128/MCB.21.19.6495-6506.2001
37. Zhang H, Shepherd AT, Eason DD, Wei S, Diaz JI, Djeu JY, Wu GD, Blanck G. Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Cell Growth Differ1999; 10:457-65; PMID:10437913
38. Osborne AR, Zhang H, Fejer G, Palubin KM, Niesen MI, Blanck G. Oct-1 maintains an intermediate, stable state ofHLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. J Biol Chem 2004; 279:28911-9; PMID:15105429; http://dx.doi.org/10.1074/jbc.M403118200
39. Pillai S, Szekeres K, Lawrence NJ, Chellappan SP, Blanck G. Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: cancer cell expression of HLA-DR. Gene 2013; 512:403-7; PMID:23041127; http://dx.doi.org/10.1016/j.gene.2012.09.092
40. Xu L, Niesen MI, Blanck G. Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit. Mol Immunol 2009; 46:569-75; PMID:18952290; http://dx.doi.org/10.1016/j.molimm.2008.07.035
41. Gage JR, Meyers C, Wettstein FO. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in reti-noblastoma protein binding and other properties. J Virol 1990; 64:723-30; PMID:2153238
42. Zwerschke W, Jansen-Durr P. Cell transformation by the E7 oncoprotein of human papillomavirus type 16: interactions with nuclear and cytoplasmic target proteins. Adv Cancer Res 2000; 78:1-29; PMID:10547667; http://dx.doi.org/10.1016/S0065-230X(08)61022-2
43. Croul S, Otte J, Khalili K. Brain tumors and polyoma-viruses. J Neurovirol 2003; 9:173-82; PMID:12707848; http://dx.doi.org/10.1080/13550280390194055
44. Helt AM, Galloway DA. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 2003; 24:159-69; PMID:12584163; http://dx.doi.org/10.1093/carcin/24.2.159
45. Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol 2014; 184:574-83; PMID:24388934; http://dx.doi.org/10.1016/j.ajpath.2013.10.028
46. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511; PMID:15229469; http://dx.doi.org/10.1038/nri1391
47. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9:57-63; PMID:19052556; http://dx.doi.org/10.1038/nrc2541
48. Taura M, Suico MA, Koyama K, Komatsu K, Miyakita R, Matsumoto C, Kudo E, Kariya R, Goto H, Kitajima S, et al. Rb/E2F1 regulates the innate immune receptor Toll-like receptor 3 in epithelial cells. Mol Cell Biol 2012; 32:1581-90; PMID:22310660; http://dx.doi.org/10.1128/MCB.06454-11
49. Garcia MA, Gallego P, Campagna M, Gonzalez-Santa-maria J, Martinez G, Marcos-Villar L, Vidal A, Esteban M, Rivas C. Activation of NF-kB pathway by virus infection requires Rb expression. PLoS One 2009; 4: e6422; PMID:19649275; http://dx.doi.org/10.1371/journal.pone.0006422
50. DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH, Marsilio E, Paucha E, Livingston DM. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988; 54:275-83; PMID:2839300; http://dx.doi.org/10.1016/0092-8674(88)90559-4
51. Harris KF, Christensen JB, Imperiale MJ. BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control. J Virol 1996; 70:2378-86; PMID:8642665
52. Krynska B, Gordon J, Otte J, Franks R, Knobler R, DeLuca A, Giordano A, Khalili K. Role of cell cycle regulators in tumor formation in transgenic mice expressing the human neurotropic virus, JCV, early protein. J Cell Biochem 1997; 67:223-30; PMID:9328827; http://dx.doi.org/10.1002/(SICI)1097-4644(19971101)67:2%3c223::AID-JCB7%3e3.0.CO;2-Z
53. Shahzad N, Shuda M, Gheit T, Kwun HJ, Cornet I, Saidj D, Zannetti C, Hasan U, Chang Y, Moore PS, et al. The T antigen locus of Merkel cell polyomavirus downregulates human Toll-like receptor 9 expression. J Virol 2013; 87:13009-19; PMID:24067965; http://dx.doi.org/10.1128/JVI.01786-13
54. Weihua X, Ramanujam S, Lindner DJ, Kudaravalli RD, Freund R, Kalvakolanu DV. The polyoma virus T antigen interferes with interferon-inducible gene expression. Proc Natl Acad Sci U S A 1998; 95:108-590; PMID:9448289; http://dx.doi.org/10.1073/pnas.95.3.1085
55. Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, Biron CA. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol 2000; 1:70-6; PMID:10881178; http://dx.doi.org/10.1038/76940
56. Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer (Review). Oncol Lett 2011; 2:5839; PMID:22848232
57. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007; 96:41-101; PMID:17981204; http://dx.doi.org/10.1016/S0065-2776(07)96002-2
58. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000; 275:6764-9; PMID:10702232; http://dx.doi.org/10.1074/jbc.275.10.6764
59. Zhou F, Chen J, Zhao KN. Human papillomavirus 16-encoded E7 protein inhibits IFN-gamma-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratino-cytes. J General Virol 2013; 94:2504-14; PMID:23956301; http://dx.doi.org/10.1099/vir.0.054486-0
60. Cook JL, Walker TA, Worthen GS, Radke JR. Role of the E1A Rb-binding domain in repression of the NF-kappa B-dependent defense against tumor necrosis factor-alpha. Proc Natl Acad Sci U S A 2002; 99:996-671; PMID:12119420; http://dx.doi.org/10.1073/pnas.162082999
61. Fera D, Marmorstein R. Different regions othe HPV-E7 and Ad-E1A viral oncoproteins bind competitively but through distinct mechanisms to the CH1 trans activation domain of p300. Biochemistry 2012; 51:952-434; PMID:23121466; http://dx.doi.org/10.1021/bi3011863
62. Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res 2010; 16:1094-9; PMID:20145169; http://dx.doi.org/10.1158/1078-0432.CCR-09-0787
63. Elfstrom KM, Herweijer E, Sundstrom K, Arnheim-Dahlstrom L. Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination: a review. Curr Opin Oncol 2014; 26:120-9; PMID:24248011; http://dx.doi.org/10.1097/CCO.0000000000000034
64. Bahrami AA, Ghaemi A, Tabarraei A, Sajadian A, Gorji A, Soleimanjahi H. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responsesin mice. J Virol Methods 2014; 206:12-8; PMID:24880067; http://dx.doi.org/10.1016/j.jviromet.2014.05.013
65. Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R, Teh M. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007; 109:1097-105; PMID:17311305; http://dx.doi.org/10.1002/cncr.22503
66. Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F, Bufo P, Battaglia M, Selvaggi FP, Carrieri G. Retinoblastoma protein expression predicts response to bacillus Calmette-Guerin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol 2010; 28:285-9; PMID:18976938; http://dx.doi.org/10.1016/j.urolonc.2008.08.003
67. Page DB, Postow MA, Callahan MK, Allison JP, Wol-chok JD. Immune modulation in cancer with antibodies. Annu Rev Med 2014; 65:185-202; PMID:24188664; http://dx.doi.org/10.1146/annurev-med-092012-112807
68. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:25264; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
69. Dissanayake SK, Thompson JA, Bosch JJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg S. Activation of tumor-specific CD4(C) T lymphocytes by major his to compatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 2004; 64:1867-74; PMID:14996751; http://dx.doi.org/10.1158/0008-5472.CAN-03-2634
70. Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(C) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res 2007; 67:4499-506; PMID:17483366; http://dx.doi.org/10.1158/0008-5472.CAN-06-3770
71. Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, Ostrand-Rosenberg S. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunol 2008; 57:389-98; PMID:17724589; http://dx.doi.org/10.1007/s00262-007-0381-5
72. Srivastava MK, Bosch JJ, Wilson AL, Edelman MJ, Ostrand-Rosenberg S. MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of non-small cell lung cancer cells. Int J Cancer 2010; 127:2612-21; PMID:20473949; http://dx.doi.org/10.1002/ijc.25462